Wall Street analyst estimates for Medpace Holdings, Inc. (MEDP): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance.
Consensus price target
$646.90 (-1 % vs price $652.01)
between $515.00 and $730.00 · 9 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $2.8B | $2.8B – $2.9B | $18.24 | 9 |
| 2027E | $3.0B | $2.9B – $3.2B | $19.70 | 9 |
| 2028E | $3.3B | $2.9B – $3.5B | $22.04 | 10 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 15 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 19 |
| Avg rating (−2 sell to +2 buy) | 0.21 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-08 | $4.82 | ||
| 2026-10-21 | $4.84 | $4.44 | +9.0% |
| 2026-07-22 | $4.25 | $3.98 | +6.8% |
| 2026-04-22 | $4.28 | $3.92 | +9.2% |
| 2026-02-09 | $4.67 | $4.19 | +11.5% |
| 2025-10-22 | $3.86 | $3.53 | +9.3% |
| 2025-07-21 | $3.10 | $2.98 | +4.0% |
| 2025-04-21 | $3.67 | $3.06 | +19.9% |
Valuation Ratios
| P/E Ratio | 36.14 |
| Price / Book | 31.14 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $421.6M | $436.2M | $704.6M | $861.0M | $925.9M | $1.14B | $1.46B | $1.89B | $2.11B | $2.53B |
| Cost of Revenue | $249.5M | $261.5M | $489.1M | $615.3M | $647.2M | $814.2M | $1.03B | $1.36B | $1.45B | $1.77B |
| Gross Profit | $172.1M | $174.7M | $215.5M | $245.7M | $278.7M | $328.2M | $432.4M | $524.5M | $656.3M | $760.6M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $61.5M | $63.4M | $75.7M | $95.2M | $92.2M | $108.4M | $131.4M | $161.4M | $180.2M | $197.6M |
| Operating Expenses | $119.6M | $109.8M | $114.5M | $118.4M | $111.7M | $129.5M | $153.7M | $187.7M | $209.4M | $225.7M |
| Operating Income | $52.5M | $64.9M | $101.0M | $127.3M | $167.0M | $198.6M | $278.7M | $336.8M | $446.9M | $534.9M |
| EBITDA | $99.5M | $111.0M | $139.8M | $150.5M | $186.6M | $223.1M | $308.1M | $362.5M | $505.2M | $570.5M |
| Interest Expense | $19.4M | $7.6M | $8.2M | $1.6M | 0 | $105,000 | $2.9M | $488,000 | 0 | 0 |
| Pre-tax Income | $22.0M | $56.9M | $94.0M | $124.8M | $168.5M | $201.9M | $282.9M | $335.7M | $475.9M | $542.4M |
| Income Tax | $8.5M | $17.8M | $20.8M | $24.4M | $23.1M | $20.0M | $37.5M | $52.9M | $71.5M | $91.3M |
| Net Income | $13.4M | $39.1M | $73.2M | $100.4M | $145.4M | $181.8M | $245.4M | $282.8M | $404.4M | $451.1M |
| EPS | $0.38 | $1.00 | $2.05 | $2.79 | $4.07 | $5.06 | $7.57 | $9.20 | $13.06 | $15.64 |
| EPS (Diluted) | $0.37 | $0.98 | $1.97 | $2.67 | $3.84 | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
| Shares Outstanding (Diluted) | 36.3 M | 39.8 M | 36.9 M | 37.6 M | 37.7 M | 37.7 M | 33.7 M | 31.8 M | 32.0 M | 29.5 M |
Price
| Price | $652.01 (closing price, October 30, 2026) |
| Market Cap | $18.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ICLR · FTRE · IQV · CRL
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of MEDP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks